Reuters logo
BRIEF-Spark Therapeutics says NASDAQ halts trading of its common stock
October 12, 2017 / 11:52 AM / in 2 months

BRIEF-Spark Therapeutics says NASDAQ halts trading of its common stock

Oct 12 (Reuters) - Spark Therapeutics Inc:

* Spark Therapeutics (once) trading of stock halted as FDA advisory committee reviews investigational gene therapy

* Spark Therapeutics Inc - U.S. ‍FDA’s cellular, tissue and gene therapies advisory committee is meeting today to review LUXTURNA (voretigene neparvovec)​

* Spark Therapeutics Inc - ‍LUXTURNA is under priority review with FDA, with an assigned prescription drug user fee act (PDUFA) date of jan. 12, 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below